|1.||Palumbo, Antonio: 53 articles (12/2015 - 07/2007)|
|2.||Anderson, Kenneth C: 49 articles (12/2015 - 11/2002)|
|3.||Richardson, Paul G: 40 articles (12/2015 - 11/2002)|
|4.||Zeldis, Jerome B: 32 articles (04/2014 - 01/2005)|
|5.||Dimopoulos, Meletios A: 30 articles (10/2015 - 03/2007)|
|6.||Rajkumar, S Vincent: 29 articles (09/2015 - 04/2005)|
|7.||List, Alan F: 24 articles (01/2014 - 12/2006)|
|8.||Knight, Robert: 23 articles (07/2015 - 02/2005)|
|9.||Hideshima, Teru: 22 articles (10/2015 - 11/2002)|
|10.||Facon, Thierry: 21 articles (12/2015 - 11/2007)|
06/01/2011 - "Also, the oral immunomodulator lenalidomide, first found to be active in advanced, relapsed multiple myeloma, was highly effective in intercepting the precursor stage, high-risk smoldering multiple myeloma from progressing. "
04/01/2010 - "Lenalidomide is an oral immunomodulatory drug that is highly effective in treating multiple myeloma, has a favorable safety profile and is now being evaluated as maintenance therapy, preventive therapy and in combination with other new agents."
02/01/2015 - "Finally, a further synergistically improved myeloma cell lysis with the daratumumab-IPH2102 combination was observed by adding lenalidomide, which suggests that more effective treatment strategies can be designed for multiple myeloma by combining daratumumab with agents that independently modulate natural killer cell function. "
11/01/2015 - "Lenalidomide is manageable and effective in multiple myeloma, particularly in elderly patients. "
09/01/2011 - "Lenalidomide is effective for extramedullary disease in relapsed or refractory multiple myeloma."
|2.||Myelodysplastic Syndromes (Myelodysplastic Syndrome)
11/01/2015 - "Lenalidomide has demonstrated remarkable efficacy for therapy of lower-risk myelodysplastic syndromes (MDS) associated with 5q(-). "
07/09/2015 - "Lenalidomide is a highly effective treatment for myelodysplastic syndrome (MDS) with deletion of chromosome 5q (del(5q)). "
09/01/2012 - "Complete Remission of del(5q) Myelodysplastic Syndrome after 7 Days of Lenalidomide Therapy Gives an Alert!"
07/01/2010 - "Efficacy of lenalidomide treatment and complete cytogenetic remission in a case of myelodysplastic syndrome with del(5q) and del(9q)."
03/01/2010 - "The beneficial effect of lenalidomide in patients with lower risk myelodysplastic syndrome with del(5q) is associated with significant increases in the proportion of bone marrow erythroid precursor cells and in the frequency of clonogenic progenitor cells, a substantial improvement in the hematopoiesis-supporting potential of bone marrow stroma and significant alterations in the adhesion profile of bone marrow CD34(+) cells."
01/01/2005 - "These data further support the use of lenalidomide as an orally administered drug for the effective treatment of angiogenesis-dependent conditions, including cancer, and suggest a potential mechanism of action."
11/01/2010 - "Lenalidomide is a novel immunomodulatory agent with a unique dual mechanism of action: its tumoricidal effect leads to direct tumor cell death, and its immunomodulatory effect keeps the tumor in remission. "
01/01/2013 - "Lenalidomide (LEN) is an immunomodulatory drug (IMiD) which exerts tumoricidal effects and has immunomodulatory, anti-inflammatory and anti-angiogenic properties that synergistically keep the tumor in remission. "
10/01/2010 - "This review outlines the mechanisms of action, the toxicity profile and the efficacy of lenalidomide, reviewing the current literature and focusing on the current status of the compound in cancer management. "
06/01/2012 - "Ongoing trials of lenalidomide combination therapy offer a treatment option for patients with advanced cancer and will better define the role of lenalidomide in solid tumors."
|4.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
10/01/2012 - "We conducted a phase II study to evaluate the safety and efficacy of lenalidomide in patients with relapsed/refractory acute myeloid leukemia (AML) and high-risk MDS with any chromosome 5 abnormality. "
01/01/2014 - "Patients who achieve transfusion independence and/or a cytogenetic response with lenalidomide have a decreased risk of progression to acute myeloid leukemia and an improved overall survival compared to non-responders. "
03/01/2013 - "Lenalidomide as a novel treatment of acute myeloid leukemia."
03/01/2011 - "Lenalidomide therapy was initiated, and the patient's skin condition improved after 6 weeks of treatment; however, his MDS progressed to acute myeloid leukemia, and he died shortly thereafter. "
08/01/2009 - "Lenalidomide-induced durable hematological and cytogenetic remission in del(5q)-associated de novo acute myeloid leukemia."
|5.||B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
01/01/2010 - "Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics."
04/01/2013 - "Lenalidomide is effective against relapsed chronic lymphocytic leukemia (CLL). "
12/01/2006 - "Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study."
04/01/2013 - "Long-term molecular remission with lenalidomide treatment of relapsed chronic lymphocytic leukemia."
05/16/2013 - "In vitro studies have demonstrated that lenalidomide repairs the T-cell immunologic synapse defect in chronic lymphocytic leukemia (CLL). "
|4.||Proteasome Endopeptidase Complex (Proteasome)
|5.||lenalidomide (CC 5013)
|1.||Stem Cell Transplantation
|2.||Drug Therapy (Chemotherapy)